Detalles de la búsqueda
1.
21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer.
N Engl J Med
; 385(25): 2336-2347, 2021 12 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-34914339
2.
Expanding the Staging Criteria for T1-2N0 Hormone-Receptor Positive Breast Cancer Patients Enrolled in TAILORx.
Ann Surg Oncol
; 29(13): 8016-8023, 2022 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-35900648
3.
Correction to: Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trial.
Breast Cancer Res Treat
; 175(1): 265-266, 2019 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-30632020
4.
21-Gene Recurrence Score for prognosis and prediction of taxane benefit after adjuvant chemotherapy plus endocrine therapy: results from NSABP B-28/NRG Oncology.
Breast Cancer Res Treat
; 168(1): 69-77, 2018 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-29128898
5.
The 21-gene Recurrence Score® assay predicts distant recurrence in lymph node-positive, hormone receptor-positive, breast cancer patients treated with adjuvant sequential epirubicin- and docetaxel-based or epirubicin-based chemotherapy (PACS-01 trial).
BMC Cancer
; 18(1): 526, 2018 May 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-29728098
6.
Breast cancer-specific survival in patients with lymph node-positive hormone receptor-positive invasive breast cancer and Oncotype DX Recurrence Score results in the SEER database.
Breast Cancer Res Treat
; 163(2): 303-310, 2017 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-28243896
7.
Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trial.
Breast Cancer Res Treat
; 165(3): 573-583, 2017 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-28664507
8.
ASO Visual Abstract: Expanding Staging Criteria in T1-2N0 Hormone Receptor-Positive Breast Cancer Patients Enrolled in TAILORx.
Ann Surg Oncol
; 29(13): 8024-8025, 2022 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-35902504
9.
The relationship between quantitative human epidermal growth factor receptor 2 gene expression by the 21-gene reverse transcriptase polymerase chain reaction assay and adjuvant trastuzumab benefit in Alliance N9831.
Breast Cancer Res
; 17(1): 133, 2015 Oct 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-26429296
10.
A population-based validation study of the DCIS Score predicting recurrence risk in individuals treated by breast-conserving surgery alone.
Breast Cancer Res Treat
; 152(2): 389-98, 2015 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-26119102
11.
Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic Disease.
J Clin Oncol
; 41(8): 1501-1510, 2023 03 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-36881998
12.
Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer.
J Clin Oncol
; 41(9): 1638-1645, 2023 03 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-36921335
13.
Gene Expression and Benefit of Chemotherapy in Women With Node-Negative, Estrogen Receptor-Positive Breast Cancer.
J Clin Oncol
; 41(20): 3565-3575, 2023 Jul 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-37406456
14.
Evaluation of the Sensitivity to Endocrine Therapy Index and 21-Gene Breast Recurrence Score in the SWOG S8814 Trial.
J Clin Oncol
; 41(10): 1841-1848, 2023 04 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36649570
15.
Prognostic value of biologic subtype and the 21-gene recurrence score relative to local recurrence after breast conservation treatment with radiation for early stage breast carcinoma: results from the Eastern Cooperative Oncology Group E2197 study.
Breast Cancer Res Treat
; 134(2): 683-92, 2012 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-22547108
16.
Endocrine Therapy Response and 21-Gene Expression Assay for Therapy Guidance in HR+/HER2- Early Breast Cancer.
J Clin Oncol
; 40(23): 2557-2567, 2022 08 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-35404683
17.
Comparison of the prognostic and predictive utilities of the 21-gene Recurrence Score assay and Adjuvant! for women with node-negative, ER-positive breast cancer: results from NSABP B-14 and NSABP B-20.
Breast Cancer Res Treat
; 127(1): 133-42, 2011 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-21221771
18.
Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial.
Lancet Oncol
; 11(1): 55-65, 2010 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-20005174
19.
Development and Validation of a Tool Integrating the 21-Gene Recurrence Score and Clinical-Pathological Features to Individualize Prognosis and Prediction of Chemotherapy Benefit in Early Breast Cancer.
J Clin Oncol
; 39(6): 557-564, 2021 02 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-33306425
20.
Expanding Criteria for Prognostic Stage IA in Hormone Receptor-Positive Breast Cancer.
J Natl Cancer Inst
; 113(12): 1744-1750, 2021 11 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-34010423